As of October 2026, retatrutide is not FDA approved, and no launch date has been set. Eli Lilly plans to submit it to the FDA in the first quarter of 2027. UCHealth says it is unlikely to reach patients before 2027, and Noom estimates approval in late 2027 or early 2028, with pharmacy availability some months after that.
When will retatrutide be FDA approved?
Eli Lilly announced on July 23, 2026 that it plans to submit a Biologics License Application (BLA) to the FDA in the first quarter of 2027, according to Drugs.com’s retatrutide page, which was last updated September 30, 2026. The same page notes that FDA review can take up to about a year, depending on the type of review, and that a filing is not an approval and timelines can change.
Noom’s early access guide uses the same filing date and estimates that a 10 to 12 month FDA review puts a realistic approval date in late 2027 or early 2028, with the drug reaching pharmacies some months after that. UCHealth says retatrutide is unlikely to become available to patients until 2027 at the soonest.
Approval is a decision the FDA has not made. The review can end in approval, rejection, or a request for more data, so treat any single date as an estimate.
Is there early access to retatrutide now?
Yes, but it is narrow. Noom reports that Eli Lilly confirmed on August 3, 2026 that a limited number of people can apply for retatrutide before FDA approval. The route uses the FDA’s expanded access pathway, which Noom describes as a case-by-case exception for people with a serious or life-threatening condition who have no comparable approved option and cannot join a clinical trial.
Noom reports that Lilly told STAT people must meet all four of these criteria:
- Age 18 or older.
- Refractory obesity, meaning a BMI of 35 or higher despite adhering to and tolerating the highest available dose of an approved obesity therapy.
- At least two serious or life-threatening obesity-related complications currently being treated.
- Unable to enroll in an ongoing trial of retatrutide or a comparable investigational drug.
Requests have to come from a treating physician, not the patient. Noom says the physician checks ClinicalTrials.gov first, then contacts Lilly’s medical affairs team, and Lilly’s general expanded-access policy promises a response within five business days of receiving the required medical information. Meeting the criteria does not guarantee access. Lilly has not said how long treatment would continue or who would cover related monitoring.
Can I sign up for a retatrutide trial?
Retatrutide is studied in clinical trials, and Drugs.com says it is available only to people enrolled in an active trial who meet that trial’s eligibility criteria. Drugs.com points readers to ClinicalTrials.gov, the U.S. National Library of Medicine’s trial registry, to search for active studies. One of Lilly’s trials, TRIUMPH-1 (NCT05929066), is listed there with the status COMPLETED, so look for the active studies on the registry rather than assuming a listed study is still enrolling.
UCHealth notes an ongoing trial called TRIUMPH-5 that compares retatrutide with tirzepatide. A registration describes a study; it is not a result, so check the registry entry for enrollment status before you act on it.
Can you buy retatrutide now?
No. Drugs.com states that retatrutide cannot be bought in pharmacies or online, and that there is no legal way to obtain it for personal use outside a trial. Under federal law, it also cannot be used in compounded medicines, according to the same page.
Products sold online as “retatrutide peptide” or as research-use vials are not legitimate retatrutide, according to Drugs.com. They are not FDA approved, are not regulated for safety, purity or dose, and may be dangerous. The National Academy of Medicine’s GLP-1 overview says the FDA has not assessed compounded GLP-1 formulations for safety, effectiveness or quality.
If a drug screen is on your mind for another reason, the guide on will delta-8 thc show on a drug test explains what labs actually detect.
How much will retatrutide cost?
Retatrutide does not have a price yet. Drugs.com says no commercial cost has been set, and that any pricing will be announced only if the medicine is approved and launched. Lilly has said only that it plans to reflect the drug’s overall value to the health care system, as reported by Noom.
What can I use today while retatrutide is not available?
Semaglutide (Wegovy, Ozempic), tirzepatide (Zepbound, Mounjaro) and orforglipron (Foundayo) are already approved, according to the Drugs.com comparison. Retatrutide is the only one of these that is not FDA approved. If you want to know which approved options fit your health history, ask your clinician. For how the drug is designed to work and what the trials measured, read How Retatrutide Works.
Before you plan around a launch date
- Check the FDA’s decision status on the filing, since Lilly’s plan is a submission and not an approval.
- Search ClinicalTrials.gov for active retatrutide studies and their eligibility criteria.
- Ask your clinician whether the early access criteria could apply to you, and what approved options are available today.
- Check any online seller’s claims against the FDA’s status before you pay.
By HealthDataConsortium.org Research Team
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.
